Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040)
5,080.00
-50.00 (-0.97%)
At close: Sep 11, 2026
Kyung Dong Pharmaceutical Revenue
Kyung Dong Pharmaceutical had revenue of 52.26B KRW in the quarter ending June 30, 2026, with 5.76% growth. This brings the company's revenue in the last twelve months to 201.12B, up 3.46% year-over-year. In the year 2025, Kyung Dong Pharmaceutical had annual revenue of 196.27B with 1.20% growth.
Revenue (ttm)
201.12B
Revenue Growth
+3.46%
P/S Ratio
0.74
Revenue / Employee
605.78M
Employees
332
Market Cap
148.84B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 196.27B | 2.34B | 1.20% |
| Dec 31, 2024 | 193.94B | 31.26B | 19.22% |
| Dec 31, 2023 | 162.67B | -20.04B | -10.97% |
| Dec 31, 2022 | 182.72B | 5.11B | 2.88% |
| Dec 31, 2021 | 177.61B | 3.78B | 2.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Ahn-Gook Pharmaceutical | 345.08B |
| Cosmax Nbt | 335.18B |
| GC WellBeing | 192.21B |
| DAE HWA Pharmaceutical | 148.75B |
| HYUNDAI BIOLAND | 140.70B |
| OPTUS Pharmaceutical | 94.47B |
| High Tech Pharm | 69.41B |